
News|Videos|July 28, 2023
Luspatercept as a First-Line Treatment for Patients With Lower-Risk MDS
Author(s)Amy Dezern, MD, MHS
Dr Amy Dezern discusses the FDA priority review for luspatercept in the first-line setting for MDS and how it may impact patients.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5






































